These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 33036377)

  • 41. Two non-small cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor receptor (EGFR) G719X and L861Q mutations benefited from aumolertinib: two cases report and review of the literature.
    Li L
    Heliyon; 2022 Sep; 8(9):e10407. PubMed ID: 36119883
    [TBL] [Abstract][Full Text] [Related]  

  • 42. First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution's clinical practice experience.
    Yu X; Zhang X; Zhang Z; Lin Y; Wen Y; Chen Y; Wang W; Zhang L
    Cancer Commun (Lond); 2018 Jul; 38(1):51. PubMed ID: 30055651
    [TBL] [Abstract][Full Text] [Related]  

  • 43. All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations.
    Ullas B; Shrinidhi N; Mansi S; Narayan S; Parveen J; Surender D; Joslia JT; Anurag M
    J Cancer Res Clin Oncol; 2023 Apr; 149(4):1541-1549. PubMed ID: 35581383
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial.
    Zhou Q; Yang JJ; Chen ZH; Zhang XC; Yan HH; Xu CR; Su J; Chen HJ; Tu HY; Zhong WZ; Yang XN; Wu YL
    J Hematol Oncol; 2016 Sep; 9(1):86. PubMed ID: 27619632
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
    Oda N; Hotta K; Ninomiya K; Minami D; Ichihara E; Murakami T; Yokoyama T; Ichikawa H; Chikamori K; Takigawa N; Ochi N; Harita S; Maeda Y; Kiura K
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):1031-1038. PubMed ID: 30276451
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon
    Yang JC; Schuler M; Popat S; Miura S; Park K; Passaro A; De Marinis F; Solca F; Märten A; Kim ES
    Front Oncol; 2022; 12():834704. PubMed ID: 35574304
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment.
    Kuiper JL; Hashemi SM; Thunnissen E; Snijders PJ; Grünberg K; Bloemena E; Sie D; Postmus PE; Heideman DA; Smit EF
    Br J Cancer; 2016 Dec; 115(12):1504-1512. PubMed ID: 27875527
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Uncommon
    Shi J; Yang H; Jiang T; Li X; Zhao C; Zhang L; Zhao S; Liu X; Jia Y; Wang Y; Xi L; Zhang S; Su C; Ren S; Zhou C
    Chin J Cancer Res; 2017 Dec; 29(6):543-552. PubMed ID: 29353977
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
    Lee VH; Leung DK; Choy TS; Lam KO; Lam PM; Leung TW; Kwong DL
    BMC Cancer; 2016 Feb; 16():147. PubMed ID: 26911310
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors.
    Zheng Z; Xie D; Su H; Lin B; Zhao L; Deng X; Chen H; Fei S; Jin X; Xie C
    Tumour Biol; 2017 Jun; 39(6):1010428317706211. PubMed ID: 28618947
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
    Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ
    BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.
    Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Hida T; Yatabe Y
    Clin Lung Cancer; 2017 Nov; 18(6):698-705.e2. PubMed ID: 28596108
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI.
    Lin L; Zhao J; Hu J; Huang F; Han J; He Y; Cao X
    J Cancer; 2018; 9(3):528-534. PubMed ID: 29483958
    [No Abstract]   [Full Text] [Related]  

  • 54. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
    Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an
    Barrón F; Cardona AF; Corrales L; Ramirez-Tirado LA; Caballe-Perez E; Sanchez G; Flores-Estrada D; Zatarain-Barrón ZL; Arrieta O;
    J Thorac Dis; 2018 Apr; 10(4):2166-2178. PubMed ID: 29850120
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of plasma T790M mutation after the first generation EGFR-TKI resistance of non-small cell lung cancer in the real world.
    Li H; Wang J; Zhang G; Li Y; Lin L; Yang H; Zhou J; Zhang L; Lv D
    J Thorac Dis; 2020 Mar; 12(3):550-557. PubMed ID: 32274120
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Meta-analysis of the impact of de novo and acquired
    Liu Y; Sun L; Xiong ZC; Sun X; Zhang SL; Ma JT; Han CB
    Onco Targets Ther; 2017; 10():2267-2279. PubMed ID: 28479857
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association between EGFR exon 19 or exon 21 mutations and survival rates after first-line EGFR-TKI treatment in patients with non-small cell lung cancer.
    Jiang H; Zhu M; Li Y; Li Q
    Mol Clin Oncol; 2019 Sep; 11(3):301-308. PubMed ID: 31384460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.